Of these two potential metastasis-related biomarkers, ATR, a protein responding to DNA damage, is mutated at a high frequency (8%) in lymphatic metastasis than in primary tumors (3%) with lung cancers, but there is no difference in ATR alteration sites between primary and lymphatic lesions. Here, ATR is linked to lung cancer.